Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Diagnostics

Monod Bio, a David Baker lab spinout, gets $25 million for biosensors

by Gina Vitale
August 19, 2022 | A version of this story appeared in Volume 100, Issue 29

 

Monod Bio, a diagnostic biosensor company spun out of David Baker’s lab at the University of Washington Institute for Protein Design, has raised $25 million in seed funding. The biosensors, created from engineered proteins, emit light when they recognize a target and can deliver results rapidly; they have been able to detect the COVID-19 spike protein, cancer receptors, and more. The money will go toward Monod’s LucCage platform, which is used to create low-cost, custom biosensors.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.